Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections

Xing, Yuanming; Chen, Lu; Feng, Yan; Zhou, Yan; Zhai, Yajing; Lu, Jun

doi:10.1186/s12879-017-2913-8

Table 1 Characteristics of included studies

From: Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections

Year	Author	Multicenter	Therapeutic purpose	Antifungals	Sample size	Age	Underlying Disease	Dosing regimen	Duration
2001	Ally	Y	D	VRC	200	18–75	Esophageal Candidiasis, AIDS	200 mg, oral, bid	14d
2001	Ally	Y	D	FLU	191	18–76	Esophageal Candidiasis, AIDS	200 mg, oral, qd	15d
2002	Lazarus	Y	P	VRC	18	23–61	HM & solid tumor	200/300 mg, oral, q12h	14d
2002	Lazarus	Y	P	FLU	6	23–62	HM & solid tumor	400 mg, oral, qd	14d
2002	Herbrecht	Y	D	VRC	144	48.5	HM, SOT, AIDS	200 mg, oral/i.v., bid	77d
2002	Herbrecht	Y	D	AMBD	133	50.5	HM, SOT, AIDS	1–1.5 mg/kg, i.v., qd	10d
2002	Walsh	Y	E	VRC	415	46.3	FN, HM or other cancers	200 mg, oral, q12h	7d
2002	Walsh	Y	E	LAMB	422	45	FN, HM or other cancers	3 mg/kg, i.v. qd	7d
2005	Kullberg	Y	D	VRC	248	53.6	Candidaemia	200 mg, bid	15d
				AMB/FLU	122	53.3	Candidaemia	AMB 0.7–1.0 mg/kg, oral/i.v., qd,	15d
				AMB/FLU	122	53.3	Candidaemia	Flu, 400 mg, oral/i.v. qd	15d
2007	Queiroz-Telles	Y	D	VRC	35	48.3	Paracoccidioidomycosis	200 mg, oral, bid	169d
2007	Queiroz-Telles	Y	D	ITRA	18	48.7	Paracoccidioidomycosis	100 mg, oral, bid	200d
2010	Wingard	Y	P	VRC	305	43	AHSCT	200 mg, oral, bid	100d
2010	Wingard	Y	P	FLU	295	43	AHSCT	400 mg, oral, qd	100d
2010	Kohno.	Y	D	VRC	54	69.9	Tuberculosis sequelae	4 mg/kg, i.v., bid	3w
2010	Kohno.	Y	D	MCF	53	72.1	Tuberculosis sequelae	150–300 mg, i.v., qd	3w
2010	Oyake 1	Y	E	VRC	46	NA	FN patients with AML	4 mg/kg, i.v., bid	9d
2010	Oyake 1	Y	E	MCF	49	NA	FN patients with AML	150 mg, i.v., qd	10d
2011	Bansal	N	D	VRC	15	36.3	CISA	200 mg (adults), 100 mg (children), oral, q12h;	12w
2011	Bansal	N	D	AMB	18	36.3	CISA	1 mg/kg, i.v., qd	14w
2011	Mattiuzzi	N	P	VRC	71	36.3	AML + MDS	300 mg, i.v., bid	20d
2011	Mattiuzzi	N	P	ITRA	52	60	AML + MDS	200 mg, i.v., qd	21d
2012	Shang	Y	D	VRC	34	37.5	Kidney transplant	4 mg/kg, i.v., q12h	2.9 m
				MCF	31	39.2	Kidney transplant	100 mg (<60 kg), qd;	3.8 m
				MCF	31	39.2	Kidney transplant	150 mg (>60 kg), i.v., qd	3.8 m
2013	Gao	Y	P	VRC	224	42.3	AHSCT	200/100 mg, oral/i.v., bid	96d
2013	Gao	Y	P	ITRA	241	42.3	AHSCT	200 mg, oral/i.v., bid	68d
2014	Hayashi	Y	P	VRC	33	NA	AHSCT	200 mg, oral, bid	NA
2014	Hayashi	Y	P	ITRA	33	NA	AHSCT	2.5 mg/kg, oral/i.v., bid	NA
2016	Maertens	Y	D	VRC	258	51.2	HM	4 mg/kg/200 mg, oral/i.v., bid	47d
2016	Maertens	Y	D	ISA	258	51.1	HM	200 mg, oral/i.v., qd	45d
2016	Oyake 2	Y	E	VRC	50	53	FN with hematopathy	4 mg/kg, i.v., bid	9d
2016	Oyake 2	Y	E	MCF	50	53	FN with hematopathy	150 mg, i.v., qd	12d

Y Yes, N No, NA not available, D definitive treatment, E empirical treatment, P prophylaxis, VRC voriconazole, FLU fluconazole, AMBD amphotericin B deoxycholate, LAMB liposome amphotericin B, AMB amphotericin B, ITRA itraconazole, MCF micafungin, ISA isavuconazole, HM hematological malignancy, SOT solid organ transplantation, FN febrile neutropenia, AHSCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, CISA chronic invasive sinus aspergillosis, MDS myelodysplastic syndrome

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us